retatrutide triple agonist glp-1 gip glucagon receptor Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Today, we shared new data

Liver Health Support The inclusion of the glucagon receptor agonist has shown promise in reducing liver fat, which is crucial for overall metabolic health and longevity

Lancet 2006, 368:1696-1705

GCL is in part regulated by GSH feedback inhibition, thus if GSH is depleted due to oxidative stress, inflammation, or exposure to xenobiotics, de novo synthesis of GSH is upregulated, as is cysteine synthesis

fun fact: the company drew an FDA warning letter in June for false claims about its compounded weight-loss drugs

The Asia-Pacific region has witnessed an alarming increase in the prevalence of diabetes in recent years